NovaDel CEO Interviews on Wall Street Reporter First FDA Approval Filing to Occur Within Next Two Months; Five Tier One Drugs Entering Proof of Concept Studies FLEMINGTON, N.J., April 19 /PRNewswire-FirstCall/ -- Gary A. Shangold, MD, president and chief executive officer of NovaDel Pharma Inc. (OTC Bulletin Board: NVDL) told http://www.wallstreetreporter.com/ viewers that the company will be filing for US FDA approval of its first drug within the next two months, and that feasibility studies of five more drug candidates are progressing on schedule with data from pilot clinical pharmacokinetic studies coming in over the course of the next several months. In an interview aired last Friday, the former Johnson & Johnson executive said the company's first product candidate for approval, lingual spray nitroglycerin, will validate the company's lingual spray technology and help advance commercial discussions with partners for its other lead products. NovaDel's patented lingual spray technology provides a convenient, non-invasive way to make drugs better and safer. The technology produces more rapid onset of action and has the potential to significantly reduce first pass liver toxicity. Patients self-administer the products just as they would a breath freshener. The company's technology is seen as especially important for innovator companies whose drugs are coming off patent and the possibility exists to create a new formulation to reduce competitive erosion of a hard earned franchise. Dr. Shangold said NovaDel's lingual spray technology could create new benefits, while protecting an innovator's existing market. He cited the attraction of faster acting versions of the popular sleep aid Ambien(R) (Sanofi) and the leading migraine drug Imitrex(R) (Glaxo), a triptan, as examples. Lingual spray versions of those two products would have clearly distinguishable advantages over the current products, which are facing relatively near term patent expirations. "NovaDel intends to excel in product life cycle management for the benefit of our customers -- whether they be the franchise protectors or the franchise builders," said Dr. Shangold. "Either way, our lingual spray offers a distinctive set of product enhancements that will translate into premium benefits for patients." Dr. Shangold said the company's cash position will enable it to complete current programs well into 2005. To hear the full interview visit http://www.wallstreetreporter.com/. About NovaDel Pharma Inc. NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the- counter drugs. The Company's proprietary lingual spray technology delivery system offers the patient (i) fast onset of action; (ii) improved drug safety by reducing the required drug dosage and reducing side effects; (iii) improved patient convenience and compliance; and (iv) enhanced dosage reliability. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies. Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the ability to develop products (independently and through collaborative arrangements), and the ability to commercialize and obtain approval for products under development. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent Annual Report and Registration Statements, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings. Contact: Barry C. Cohen VP Business & New Product Development 908 782-3431 x 2160 NovaDel Pharma Inc. Thomas Redington 203 222-7399 212 926-1733 DATASOURCE: NovaDel Pharma Inc. CONTACT: Barry C. Cohen, VP Business & New Product Development, NovaDel Pharma Inc., +1-908-782-3431, ext. 2160; Thomas Redington, +1-203-222-7399, +1-212-926-1733, , for NovaDel Pharma Inc. Web site: http://www.wallstreetreporter.com/

Copyright